Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb (BMS)
Participants will be randomised to receive Nivolumab and Relatlimab in combination with platinum doublet chemotherapy, or Nivolumab in combination with platinum doublet chemotherapy, on it's own. Participants will only receive two types of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.